Evotec SE announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-se—bayer-discontinues-clinical-development-candidate-eliapixant-bay1817080-evotec-regains-the-rights-to-all-p2x3-assets-6141